With the support of Innosuisse, we will further optimize our formulation and develop a zero-waste OctoPatch®, which will help us meet our sustainability goals. For these tasks, the group of Drug Formulation and Delivery at ETH received the Innosuisse innovation grant worth CHF 305’624.00. Innosuisse is the Swiss Innovation Agency with the goal to promote science-based innovations aligned with the economic and societal interests of Switzerland.
Read the summary of the project at https://www.aramis.admin.ch/Texte/?ProjectID=53460. Learn more about Innosusse at https://www.innosuisse.ch/inno/en/home.html.
Related items
OBaris is excited to share that we joined the Swiss National Startup Team! Represented by
OBaris wins Stage III Venture Kick and receives additional CHF 100’000! Read the announcem
OBaris receives CHF 150’000 for the accelerated market entry from Gebert Rüf Foundation! A